CEO Blog

August 21, 2014

Recent News Events Highlight the Dangers of Pathogens

Few Americans alive today remember the days before the widespread use of vaccines and antibiotics when a respiratory infection that today would be considered little more than an inconvenience could lead to death and when outbreaks of childhood viruses such as measles could kill hundreds. The complacency about infectious diseases that has arisen throughout the developed world is now being jolted, however, by recent news about infectious diseases in general and specific outbreaks in particular.

Read More…

August 15, 2014

The World Health Organization comments on a post-antibiotic era

Recently, the World Health Organization (WHO) announced that the rise and rapid spread of antibiotic-resistant bacteria raises threatens the achievements of modern medicine. “A post antibiotic era – in which common infections and minor injuries can kill — is a very real possibility for the 21st century,” the organization concluded.

Read More…

July 24, 2014

British Prime Minister David Cameron: Antibiotic Resistance Threatens to Plunge the World Back to the Dark Ages of Medicine

British Prime Minister David Cameron warned earlier this month that the world is in danger of being thrust back into the dark ages of medicine unless action is taken to tackle to growing threat of antibiotic resistance. Cameron’s comments followed those last year from Dame Sally Davies, Britain’s chief medical officer, who warned Parliament that the rise in drug-resistant bacteria raised the prospect of a civil emergency. She described an “apocalyptic” scenario in which people undergoing simple operations in 20 years die of routine infections.

Read More…

June 12, 2014

RUTHIGEN CLEARED TO INITIATE HUMAN CLINICAL TRIALS FOR RUT58-60 IN THE U.S.

SANTA ROSA, Calif. — (June 12, 2014) — Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, is pleased to announce today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application without a clinical hold to begin human clinical testing of RUT58-60. Read More…

June 3, 2014

CEO’s Letter to Shareholders

On June 3, 2014, Ruthigen filed a letter to its shareholders on Form 8-K with the U.S. Security and Exchange Commission. Click here to view the letter

March 31, 2014

Ruthigen Corporate Presentation – March 2014